Our research in Musculoskeletal Diseases (MSD) focuses on discovering innovative therapies for muscle wasting and bone disorders. Novartis has a long history in the treatment of disorders of bone metabolism, such as osteoporosis but currently available therapies for osteoporosis do not effectively prevent non-vertebral bone fractures.
Our strategy is therefore to discover and develop novel anabolic agents that stimulate bone formation rather than slowing down bone loss. In the area of muscle wasting, our approach is focused on developing compounds that either stimulate anabolic pathways or inhibit catabolic pathways in skeletal muscle.
Our MSD research concentrates on muscle wasting associated with disuse (i.e. from other diseases such as cancer, chronic obstructive pulmonary disease, and aging) andosteoporosis.